Abstract
Aim. To assess drug consumption of the group A07E “Intestinal anti-inflammatory agents” in Ukraine and European countries in 2015-2017.Materials and methods. Data from the “Pharmexplorer” information system of Morion company were used to analyze the assortment and the consumption volumes of intestinal anti-inflammatory agents in Ukraine. The volumes, structure and dynamics of drug consumption of this group in Ukraine was assessed based on the number of the consumed defined daily doses (DDD) of drugs using the ATC/DDD methodology and the number of packs sold. The level of consumption of the drugs studied by the indicator “DDDs/1000 inhabitants/day” in the countries of Europe was determined by the statistical data of these countries.Results. The intestinal anti-inflammatory agents were presented in Ukraine in 2015-2017 in the number of 4 international non-patented names, 22-27 trade names (TN), mainly of foreign production with a high price for a pack. The number of TNs of drugs of this group and volumes of their consumption (by the number of packs sold and the number of the consumed DDDs) increased in Ukraine from 2015 to 2017. The largest number of packs sold was determined for sulfasalazine. The level of consumption of intestinal anti inflammatory agents by the indicator “DDDs/1000 inhabitants/day” in Ukraine did not correspond tothe level of drug consumption of this group in European countries (Norway, Lithuania, Latvia, Estonia) in2015-2017, and it was the lowest among the countries studied. The largest volumes of drug consumption ofthis group were determined in Norway. Mesalazine was ranked first by the number of the consumed DDDsin Norway, Lithuania and Estonia in 2015-2017, and sulfasalazine – in Latvia. The leadership of sulfasalazineand mesalazine varied over the years in Ukraine.Conclusions. The volumes of drug consumption of the group A07E “Intestinal anti-inflammatory agents” by the number of packs sold and the number of the consumed DDDs increased in Ukraine from 2015 to 2017. The level of drug consumption of this group by the indicator “DDDs/1000 inhabitants/day” in Ukraine during 2015-2017 did not correspond to the level of consumption of the intestinal anti-inflammatory agentsin European countries.
Highlights
IntroductionПротизапальні засоби, що застосовуються при захворюваннях кишечника, у 2015-2017 рр
The volumes, structure and dynamics of drug consumption of this group in Ukraine was assessed based on the number of the consumed defined daily doses (DDD) of drugs using the ATC/DDD methodology and the number of packs sold
The level of consumption of the drugs studied by the indicator “DDDs/1000 inhabitants/day” in the countries of Europe was determined by the statistical data of these countries
Summary
Протизапальні засоби, що застосовуються при захворюваннях кишечника, у 2015-2017 рр. Кількість ТН ЛЗ цієї групи та обсяги їх споживання (за кількістю реалізованих упаковок та кількістю спожитих DDD) збільшились в Україні з 2015 по 2017 р. Що застосовуються при захворюваннях кишечника, за показником «DDDs/1000 жителів/день» в Україні в 2015-2017 рр. Не відповідав рівню споживання препаратів цієї групи в країнах Європи (Норвегії, Литві, Латвії, Естонії) і був найнижчим серед досліджуваних країн. Обсяги споживання ЛЗ групи А07Е «Протизапальні засоби, що застосовуються при захворюваннях кишечника» в Україні за кількістю реалізованих упаковок та кількістю спожитих DDD збільшились із 2015 по 2017 рік. Не відповідав рівню споживання протизапальних засобів, що застосовуються при захворюваннях кишечника, в країнах Європи. Ключові слова: протизапальні засоби, що застосовуються при захворюваннях кишечника; асортимент лікарських засобів; фармацевтичний ринок; ATC/DDD-методологія; споживання лікарських засобів
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
